Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer in Japan: The ARASHI Study
International Journal of Urology · 2025
DOI: 10.1111/iju.70235 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Kazuhiro Suzuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gunma University Graduate School of Medicine, Gunma, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer HealthCare Pharmaceuticals.
Abstract (Originalsprache)
Objectives
To describe clinical use and outcomes of androgen receptor signaling inhibitors (ARSIs) darolutamide, enzalutamide, and apalutamide in patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC) in Japan.
Methods
This retrospective, observational study examined health claims data from acute care hospitals (Medical Data Vision Co. Ltd. database) in Japan, for patients with nmCRPC initiating an ARSI between February 2020 and April 2023. Key outcomes were time to initial ARSI discontinuation and time to progression to metastatic castration‐resistant prostate cancer (mCRPC).
Results
Of 2746 eligible patients, 418 (15%) received darolutamide, 1898 (69%) enzalutamide, and 430 (16%) apalutamide. Median follow‐up was 18.1 months for darolutamide, 20.9 months for enzalutamide, and 24.6 months for apalutamide. The proportion of patients initiating treatment at label dose was 78% (darolutamide), 58% (enzalutamide), and 62% (apalutamide). Median times (95% CI) to discontinuation (unadjusted Kaplan–Meier [KM]) were 16.1 months (13.3–21.0) for darolutamide, 12.3 months (11.3–13.3) for enzalutamide, and 7.1 months (5.3–9.7) for apalutamide. The KM‐estimated proportions of patients progressing to mCRPC by 24 months (95% CI) were 27% (23–33) for darolutamide, 37% (34–39) for enzalutamide, and 40% (35–45) for apalutamide. The results were consistent across inverse probability of treatment weighting sensitivity analyses.
Conclusions
We observed that a higher proportion of patients receiving darolutamide were likely to stay on treatment longer than patients receiving enzalutamide or apalutamide, and progression to mCRPC appeared to be delayed in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.
- Bayer Yakuhin Ltd, Osaka, Japan.
- Bayer Consumer Care AG, Basel, Switzerland.
- Department of Urology, Toho University Sakura Medical Center, Chiba, Japan.
ORCID-Profile: Kazuhiro Suzuki, Hiroyoshi Suzuki
Förderung
- Bayer HealthCare Pharmaceuticals
Zitieren
APA
Suzuki, K., Khan, N., Taguchi, T., Hattori, K., Chen, G., Ghadessi, M., Constantinovici, N., Quintero, V., & Suzuki, H. (2025). Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer in Japan: The ARASHI Study. International Journal of Urology. https://doi.org/10.1111/iju.70235
Vancouver
Suzuki K, Khan N, Taguchi T, Hattori K, Chen G, Ghadessi M, et al. Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer in Japan: The ARASHI Study. International Journal of Urology. 2025. doi:10.1111/iju.70235
BibTeX
@article{Suzuki2025,
author = {Suzuki, Kazuhiro and Khan, Nasreen and Taguchi, Tomoyuki and Hattori, Kana and Chen, Guifang and Ghadessi, Mercedeh and Constantinovici, Niculae and Quintero, Vanessa and Suzuki, Hiroyoshi},
title = {Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer in Japan: The ARASHI Study},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70235}
}
EUVIMED